NLSP Key Statistics, Chart & Performance
The current stock price of NLSP is 0.762 USD. In the past month the price decreased by -64.06%. In the past year, price decreased by -78.83%.
NLSP Technical Analysis
NLSP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NLSP. NLSP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NLSP Financial Highlights
Over the last trailing twelve months NLSP reported a non-GAAP Earnings per Share(EPS) of -2.93. The EPS increased by 77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -181.68% | ||
| ROE | -288.47% | ||
| Debt/Equity | 0 |
NLSP Forecast & Estimates
NLSP Ownership
NLSP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.12 | 987.61B | ||
| JNJ | JOHNSON & JOHNSON | 20.48 | 574.955B | ||
| MRK | MERCK & CO. INC. | 21.74 | 292.01B | ||
| PFE | PFIZER INC | 9.01 | 153.798B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.99 | 123.713B | ||
| ZTS | ZOETIS INC | 18.54 | 56.1B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.49 | 25.427B | ||
| VTRS | VIATRIS INC | 6.15 | 17.921B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.75 | 12.337B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.72 | 9.236B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NLSP
Company Profile
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
Company Info
NLS PHARMACEUTICS LTD
The Circle 6
Zurich ZUERICH CH-6370 CH
CEO: Alexander Zwyer
Employees: 1
Phone: 41445122150
NLS PHARMACEUTICS LTD / NLSP FAQ
What does NLSP do?
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
What is the stock price of NLS PHARMACEUTICS LTD today?
The current stock price of NLSP is 0.762 USD. The price increased by 2.97% in the last trading session.
What is the dividend status of NLS PHARMACEUTICS LTD?
NLSP does not pay a dividend.
How is the ChartMill rating for NLS PHARMACEUTICS LTD?
NLSP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of NLS PHARMACEUTICS LTD (NLSP) based on its PE ratio?
NLS PHARMACEUTICS LTD (NLSP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.93).
What is the ownership structure of NLS PHARMACEUTICS LTD (NLSP)?
You can find the ownership structure of NLS PHARMACEUTICS LTD (NLSP) on the Ownership tab.